Study of the immunogenicity, safety, and tolerability of PF-05212366 in healthy toddlers aged 12 to less than 18 Months and 18 to less than 24 months

A Phase 2, Randomized, Controlled, Observer-Blinded Study Conducted to Describe the Immunogenicity, Safety, and Tolerability of a Neisseria meningitides Serogroup B Bilvalent recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) When Administered to Healthy Toddlers Aged 12 to less than 18 Months or 18 to less than 24 Months

Category & Conditions:
Vaccine-related Conditions
PF-05212366 (Bivalent rLP2086) Identifier (NCT):
Protocol ID:
Open Plain Language Summary Result:Click here